These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 36963128)

  • 1. Outcome reporting in randomized trials in gout: A systematic scoping review from the OMERACT gout working group assessing the uptake of the core outcome set.
    Morillon MB; Nørup A; Singh JA; Dalbeth N; Taylor WJ; Kennedy MA; Pedersen BM; Grainger R; Tugwell P; Perez-Ruiz F; Diaz-Torne C; Edwards NL; Shea B; Ellingsen TJ; Christensen R; Stamp LK;
    Semin Arthritis Rheum; 2023 Jun; 60():152191. PubMed ID: 36963128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OMERACT endorsement of measures of outcome for studies of acute gout.
    Singh JA; Taylor WJ; Dalbeth N; Simon LS; Sundy J; Grainger R; Alten R; March L; Strand V; Wells G; Khanna D; McQueen F; Schlesinger N; Boonen A; Boers M; Saag KG; Schumacher HR; Edwards NL
    J Rheumatol; 2014 Mar; 41(3):569-73. PubMed ID: 24334651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes assessed in trials of gout and accordance with OMERACT-proposed domains: a systematic literature review.
    Araújo F; Cordeiro I; Ramiro S; Falzon L; Branco JC; Buchbinder R
    Rheumatology (Oxford); 2015 Jun; 54(6):981-93. PubMed ID: 25398382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the effect of interventions for axial spondyloarthritis according to the endorsed ASAS/OMERACT core outcome set: a meta-research study of trials included in Cochrane reviews.
    Andreasen RA; Kristensen LE; Baraliakos X; Strand V; Mease PJ; de Wit M; Ellingsen T; Hansen IMJ; Kirkham J; Wells GA; Tugwell P; Maxwell L; Boers M; Egstrup K; Christensen R
    Arthritis Res Ther; 2020 Jul; 22(1):177. PubMed ID: 32711571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. OMERACT Core outcome measurement set for shared decision making in rheumatic and musculoskeletal conditions: a scoping review to identify candidate instruments.
    Naye F; Toupin-April K; de Wit M; LeBlanc A; Dubois O; Boonen A; Barton JL; Fraenkel L; Li LC; Stacey D; March L; Barber CEH; Hazlewood GS; Guillemin F; Bartlett SJ; Berthelsen DB; Mather K; Arnaud L; Akpabio A; Adebajo A; Schultz G; Sloan VS; Gill TK; Sharma S; Scholte-Voshaar M; Caso F; Nikiphorou E; Nasef SI; Campbell W; Meara A; Christensen R; Suarez-Almazor ME; Jull JE; Alten R; Morgan EM; El-Miedany Y; Singh JA; Burt J; Jayatilleke A; Hmamouchi I; Blanco FJ; Fernandez AP; Mackie S; Jones A; Strand V; Monti S; Stones SR; Lee RR; Nielsen SM; Evans V; Srinivasalu H; Gérard T; Demers JL; Bouchard R; Stefan T; Dugas M; Bergeron F; Beaton D; Maxwell LJ; Tugwell P; Décary S
    Semin Arthritis Rheum; 2024 Apr; 65():152344. PubMed ID: 38232625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome measures in acute gout: a systematic literature review.
    Dalbeth N; Zhong CS; Grainger R; Khanna D; Khanna PP; Singh JA; McQueen FM; Taylor WJ
    J Rheumatol; 2014 Mar; 41(3):558-68. PubMed ID: 24334652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The OMERACT Core Domain Set for Clinical Trials of Shoulder Disorders.
    Ramiro S; Page MJ; Whittle SL; Huang H; Verhagen AP; Beaton DE; Richards P; Voshaar M; Shea B; van der Windt DA; Kopkow C; Lenza M; Jain NB; Richards B; Hill C; Gill TK; Koes B; Foster NE; Conaghan PG; Smith T; Malliaras P; Roe Y; Gagnier JJ; Buchbinder R
    J Rheumatol; 2019 Aug; 46(8):969-975. PubMed ID: 30709947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can we decide which outcomes should be measured in every clinical trial? A scoping review of the existing conceptual frameworks and processes to develop core outcome sets.
    Idzerda L; Rader T; Tugwell P; Boers M
    J Rheumatol; 2014 May; 41(5):986-93. PubMed ID: 24584917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-reported outcomes in chronic gout: a report from OMERACT 10.
    Singh JA; Taylor WJ; Simon LS; Khanna PP; Stamp LK; McQueen FM; Neogi T; Gaffo AL; Becker MA; MacDonald PA; Dabbous O; Strand V; Dalbeth ND; Aletaha D; Edwards NL; Schumacher HR
    J Rheumatol; 2011 Jul; 38(7):1452-7. PubMed ID: 21724715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How well are the ASAS/OMERACT Core Outcome Sets for Ankylosing Spondylitis implemented in randomized clinical trials? A systematic literature review.
    Bautista-Molano W; Navarro-Compán V; Landewé RB; Boers M; Kirkham JJ; van der Heijde D
    Clin Rheumatol; 2014 Sep; 33(9):1313-22. PubMed ID: 24970597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome Measures in Rheumatology - Interventions for medication Adherence (OMERACT-Adherence) Core Domain Set for Trials of Interventions for Medication Adherence in Rheumatology: 5 Phase Study Protocol.
    Kelly A; Tong A; Tymms K; March L; Craig JC; De Vera M; Evans V; Hassett G; Toupin-April K; van den Bemt B; Teixeira-Pinto A; Alten R; Bartlett SJ; Campbell W; Dawson T; Gill M; Hebing R; Meara A; Nieuwlaat R; Shaw Y; Singh JA; Suarez-Almazor M; Sumpton D; Wong P; Christensen R; Beaton D; de Wit M; Tugwell P;
    Trials; 2018 Mar; 19(1):204. PubMed ID: 29587864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishing a core domain set to measure rheumatoid arthritis flares: report of the OMERACT 11 RA flare Workshop.
    Bykerk VP; Lie E; Bartlett SJ; Alten R; Boonen A; Christensen R; Furst DE; Hewlett S; Leong AL; Lyddiatt A; March L; May JE; Montie P; Orbai AM; Pohl C; Scholte Voshaar M; Woodworth T; Bingham CO; Choy EH
    J Rheumatol; 2014 Apr; 41(4):799-809. PubMed ID: 24584927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of the OMERACT filter to measures of core outcome domains in recent clinical studies of acute gout.
    Taylor WJ; Redden D; Dalbeth N; Schumacher HR; Edwards NL; Simon LS; John MR; Essex MN; Watson DJ; Evans R; Rome K; Singh JA
    J Rheumatol; 2014 Mar; 41(3):574-80. PubMed ID: 24429178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using serum urate as a validated surrogate end point for flares in patients with gout: protocol for a systematic review and meta-regression analysis.
    Morillon MB; Stamp L; Taylor W; Fransen J; Dalbeth N; Singh JA; Christensen R; Lassere M
    BMJ Open; 2016 Sep; 6(9):e012026. PubMed ID: 27650765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interventions for tophi in gout.
    Sriranganathan MK; Vinik O; Bombardier C; Edwards CJ
    Cochrane Database Syst Rev; 2014 Oct; (10):CD010069. PubMed ID: 25330136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Febuxostat for treating chronic gout.
    Tayar JH; Lopez-Olivo MA; Suarez-Almazor ME
    Cochrane Database Syst Rev; 2012 Nov; 11(11):CD008653. PubMed ID: 23152264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Achieving Consensus on Total Joint Replacement Trial Outcome Reporting Using the OMERACT Filter: Endorsement of the Final Core Domain Set for Total Hip and Total Knee Replacement Trials for Endstage Arthritis.
    Singh JA; Dowsey MM; Dohm M; Goodman SM; Leong AL; Scholte Voshaar MMJH; Choong PF
    J Rheumatol; 2017 Nov; 44(11):1723-1726. PubMed ID: 28089984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colchicine for acute gout.
    van Echteld I; Wechalekar MD; Schlesinger N; Buchbinder R; Aletaha D
    Cochrane Database Syst Rev; 2014 Aug; (8):CD006190. PubMed ID: 25123076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.